Kurs
+8,41%
Likviditet
47,3 MNOK
Kalender
| Tid* | ||
| 2025-04-24 | N/A | Årsstämma |
| 2025-02-26 | N/A | Bokslutskommuniké 2024 |
| 2025-01-06 | N/A | Extra Bolagsstämma 2025 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-12 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2024-04-11 | - | Årsstämma |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2023-04-26 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-08-31 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2022-04-28 | - | Årsstämma |
| 2022-03-01 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | 15-10 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-28 | - | Årsstämma |
| 2021-04-16 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2021-03-22 | - | Extra Bolagsstämma 2021 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-21 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-11 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2020-06-10 | - | Årsstämma |
| 2020-05-26 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2019-04-25 | - | Årsstämma |
| 2019-02-18 | - | Extra Bolagsstämma 2019 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-31 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2018-05-30 | - | Årsstämma |
| 2018-05-30 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-12-20 | - | Extra Bolagsstämma 2017 |
| 2017-11-22 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-23 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2017-05-24 | - | Årsstämma |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-23 | - | Kvartalsrapport 2016-Q3 |
| 2016-10-12 | - | Extra Bolagsstämma 2016 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-31 | - | Kapitalmarknadsdag 2016 |
| 2016-05-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2016-05-19 | - | Årsstämma |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-17 | - | Kapitalmarknadsdag 2015 |
| 2015-10-21 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-27 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-09 | - | Årsstämma |
| 2014-11-12 | - | Extra Bolagsstämma 2014 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Oslo, Norway, 9 March 2021
Nordic Nanovector ASA (OSE: NANOV) announces that its Interim CEO, Dr Lars Nieba will present a corporate overview, via live webcast, and host one-on-one meetings with investors at the Carnegie's upcoming Nordic Virtual Healthcare Seminar 2021, taking place 9-12 March 2021.
Presentations details are as follows:
Carnegie Nordic Virtual Healthcare Seminar 2021
Date: Friday, 12 March 2021
Time: 12:00 (noon) - 12:30 CET
The company presentation will be available on Nordic Nanovector's Investors and Media page at the same time.
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.